Total Testosterone: When to Order This Test

What Total Testosterone Actually Measures

Total testosterone captures both the protein-bound and free fractions of testosterone circulating in your blood. Approximately 44% binds tightly to sex hormone-binding globulin (SHBG), another 50% binds loosely to albumin, and only 2 to 3% circulates unbound as free testosterone [1]. The total number reflects all three pools combined.

This distinction matters clinically. A man with high SHBG from liver disease or aging may show a "normal" total testosterone while his bioavailable fraction is genuinely low. Conversely, obesity suppresses SHBG, which can drag total testosterone readings down even when free testosterone remains adequate [2]. The Endocrine Society's 2018 guideline, authored by Bhasin et al., recommends starting with total testosterone and adding free testosterone or SHBG only when the total value is borderline or when binding-protein abnormalities are suspected [3].

LC-MS/MS is the reference method. Immunoassays are common in clinical labs but can overestimate values at low concentrations (below 150 ng/dL), which is why the CDC's Hormone Standardization Program now encourages mass spectrometry-based reporting [4]. If your lab report does not specify the method, ask. It changes how confidently you can interpret a borderline result.

Clinical Indications: When to Order in Men

The right time to check total testosterone is when symptoms and clinical suspicion align. A fishing expedition without symptoms rarely changes management.

The Endocrine Society recommends testing men who present with specific signs or symptoms of testosterone deficiency: reduced libido, erectile dysfunction, decreased spontaneous erections, breast discomfort or gynecomastia, loss of body hair, very small or shrinking testes, inability to father children, height loss or low-trauma fracture, and hot flashes [3]. The AUA's 2018 guideline adds that screening should occur in men with type 2 diabetes, HIV/AIDS, end-stage renal disease, COPD, or chronic opioid use, because prevalence of hypogonadism in these populations reaches 30 to 50% [5].

A single low reading is not enough. The guideline states: "The diagnosis of hypogonadism requires the presence of symptoms AND at least two total testosterone measurements obtained on separate mornings" [3]. This requirement exists because testosterone fluctuates day to day by as much as 15 to 20% [6].

The NHANES III dataset (N=1,486 men aged 20 to 90) established the population-based reference of 264 to 916 ng/dL that most labs now cite [7]. But context matters more than cutoffs. A 35-year-old presenting with fatigue and a level of 310 ng/dL warrants different scrutiny than an asymptomatic 70-year-old at the same number.

Clinical Indications: When to Order in Women

Testosterone testing in women serves a different diagnostic purpose. The primary indication is suspected androgen excess, not deficiency.

The American College of Obstetricians and Gynecologists (ACOG) recommends checking total testosterone in women presenting with hirsutism, treatment-resistant acne, androgenic alopecia, or menstrual irregularity when PCOS is in the differential [8]. The Endocrine Society's PCOS guideline (Legro et al., 2013) specifies that total testosterone, along with free testosterone or DHEA-S, should be measured to document biochemical hyperandrogenism, one of the three Rotterdam criteria [9].

Markedly elevated total testosterone (above 200 ng/dL in a premenopausal woman) raises concern for an androgen-secreting tumor of the ovary or adrenal gland and warrants imaging [10]. This is not common, but missing it has serious consequences.

On the deficiency side, some clinicians order testosterone in postmenopausal women reporting persistent low libido despite adequate estrogen replacement. The International Society for the Study of Women's Sexual Health (ISSWSH) issued a 2019 Global Consensus Position Statement acknowledging that "testosterone therapy may be considered for postmenopausal women with hypoactive sexual desire disorder (HSDD) after a thorough clinical assessment" [11]. Baseline testing before starting therapy is standard practice in that workflow.

How to Collect the Sample Correctly

A misdrawn sample produces a misleading number. Timing and preparation are not optional.

Testosterone secretion follows a circadian rhythm that peaks between 6:00 and 9:00 AM and falls by 20 to 25% by afternoon [6]. The Endocrine Society explicitly recommends drawing between 7:00 and 10:00 AM [3]. This rhythm blunts somewhat after age 45 to 50, but morning draws remain the standard across all age groups.

Fasting is preferred. Glucose ingestion acutely suppresses testosterone by up to 25% for 1 to 2 hours, as demonstrated in a study of 74 men with normal glucose tolerance (Caronia et al., JCEM, 2012) [12]. A patient who eats a large breakfast and then draws blood at 10:30 AM may receive a falsely low value that triggers unnecessary follow-up.

Acute illness, poor sleep the night before, high-intensity exercise within 12 hours, and recent alcohol intake all introduce noise. The AUA guideline recommends deferring testing during acute illness [5]. Obstructive sleep apnea itself lowers testosterone, but a single bad night can produce a transiently low reading that does not reflect the patient's baseline.

Medications that affect testosterone levels should be reviewed before ordering: opioids suppress the HPG axis dose-dependently, with prevalence of hypogonadism reaching 75% in men on long-term opioid therapy (Rubinstein et al., 2013, N=81) [13]. Glucocorticoids, 5-alpha reductase inhibitors, and exogenous androgens or anabolic steroids each alter the result in different directions.

Interpreting the Results: Normal, Low, and High

Start with the number, then integrate it with the clinical picture. Neither the number nor the symptoms alone confirm a diagnosis.

For adult men, the harmonized reference range using LC-MS/MS is 264 to 916 ng/dL (9.2 to 31.8 nmol/L) based on the Framingham Heart Study, NHANES III, and European Male Aging Study data pooled by Travison et al. (2017, N=9,054) [14]. The Endocrine Society uses 300 ng/dL as a pragmatic threshold below which symptoms become more likely, though this is a guideline convenience, not a biological cliff.

Values between 200 and 300 ng/dL sit in a gray zone. Here, repeating the draw and adding free testosterone (calculated from total testosterone, SHBG, and albumin via the Vermeulen equation) helps clarify whether the patient has genuine tissue-level androgen deficiency [3].

For adult premenopausal women, Quest and LabCorp typically report 15 to 70 ng/dL as the reference interval. Post-menopausal women usually fall between 10 and 40 ng/dL. A level above 150 ng/dL in any woman, regardless of menopausal status, requires rapid workup for neoplasm [10].

High testosterone in men is less commonly a clinical problem but does arise in the context of exogenous androgen use, androgen-secreting tumors, congenital adrenal hyperplasia, or hyperthyroidism (which raises SHBG, paradoxically increasing total testosterone while free testosterone may stay normal) [1].

Low testosterone in men triggers a secondary question: is the cause testicular (primary) or hypothalamic-pituitary (secondary)? Measuring LH and FSH alongside the confirmatory second draw separates the two. LH above 9.4 IU/L with low testosterone points to primary hypogonadism. Low or inappropriately normal LH with low testosterone suggests secondary hypogonadism and warrants pituitary MRI if the cause is not obvious (obesity, opioids, sleep apnea) [3].

How Total Testosterone Guides Treatment Decisions

The test result does not exist in isolation. It anchors a treatment algorithm that includes symptom burden, comorbidities, and patient goals.

The Endocrine Society recommends testosterone therapy for men with "unequivocally low serum testosterone concentrations AND clinical symptoms attributable to androgen deficiency" [3]. The TRAVERSE trial (N=5,204 men aged 45 to 80 with hypogonadism and cardiovascular risk factors), published in the New England Journal of Medicine in 2023, confirmed that transdermal testosterone did not increase major adverse cardiovascular events versus placebo over a mean follow-up of 33 months (HR 0.99; 95% CI, 0.81 to 1.21) [15]. That finding shifted the risk-benefit calculus for older men with borderline indications.

For women with HSDD, the ADORE trial (N=3,035) demonstrated that a 300 mcg/day testosterone patch produced a statistically significant increase in satisfying sexual episodes versus placebo (2.1 vs. 0.7 additional episodes per 4 weeks, P<0.001) [16].

Monitoring intervals matter too. After starting TRT, the AUA recommends rechecking total testosterone at 3 months, then every 6 to 12 months, alongside hematocrit (to watch for erythrocytosis above 54%) and PSA [5].

Factors That Lower Total Testosterone

Several modifiable and non-modifiable factors suppress total testosterone levels. Understanding them helps clinicians distinguish true hypogonadism from reversible suppression.

Obesity is the single largest modifiable contributor. The European Male Aging Study (EMAS, N=3,219) found that a BMI increase of 5 kg/m² was associated with a decline of 50 to 60 ng/dL in total testosterone, an effect comparable to 10 years of aging [17]. Weight loss of 10% or more can partially reverse this suppression without pharmacotherapy.

Aging produces a gradual decline of roughly 1 to 2% per year after age 30, though the Baltimore Longitudinal Study of Aging showed significant inter-individual variability (some men maintain levels above 500 ng/dL into their 70s) [18].

Other suppressors include chronic opioid use, type 2 diabetes (prevalence of low testosterone: 25 to 40% per ADA screening data), obstructive sleep apnea, chronic glucocorticoid exposure, and excessive alcohol intake [5][13]. Addressing these root causes before initiating TRT is a core principle of both the Endocrine Society and AUA guidelines.

Factors That Raise Total Testosterone

Lifestyle interventions can meaningfully increase total testosterone when the suppression is functional rather than organic.

Resistance training produces the most consistent effect. A meta-analysis by Kumagai et al. (2016, 21 RCTs) found that resistance exercise programs lasting 6 weeks or longer increased resting total testosterone by a weighted mean of 49 ng/dL in previously sedentary men [19]. Sleep optimization also helps: restricting healthy young men to 5 hours of sleep per night for one week reduced testosterone by 10 to 15% (Leproult and Van Cauter, JAMA, 2011, N=10) [20].

For men with confirmed hypogonadism who do not respond to lifestyle changes, testosterone replacement (injections, gels, patches, or pellets) is the pharmacologic intervention. Clomiphene citrate, an off-label selective estrogen receptor modulator, raises endogenous testosterone by stimulating LH secretion and is sometimes used in younger men who wish to preserve fertility [5].

In women with elevated testosterone from PCOS, first-line pharmacologic management is combined oral contraceptives, which raise SHBG and reduce free androgen levels. Spironolactone (50 to 200 mg daily) serves as an androgen receptor blocker for refractory hirsutism [9]. Metformin lowers testosterone modestly in insulin-resistant PCOS patients but is not first-line for hyperandrogenism per the 2023 International PCOS Guideline update [21].

When Repeat or Additional Testing Is Needed

A single total testosterone value sometimes opens more questions than it answers. Knowing when to extend the workup prevents both over-treatment and missed diagnoses.

Repeat the morning draw if the first value is low or borderline. This is not a suggestion. The Endocrine Society requires it for diagnosis [3]. If the second value confirms low total testosterone, add LH, FSH, prolactin, and a comprehensive metabolic panel. Elevated prolactin (above 25 ng/mL in men) or markedly suppressed LH warrants pituitary MRI to rule out prolactinoma or other sellar masses [3].

Free testosterone (or SHBG with calculated free testosterone) is indicated when total testosterone is 200 to 400 ng/dL, the patient has conditions that alter SHBG (obesity, liver disease, aging, thyroid dysfunction), or the clinical picture does not match the total testosterone number [5].

Estradiol should be measured in men with gynecomastia or when initiating aromatase inhibitor therapy alongside TRT. DHEA-S and androstenedione are added to the panel in women when an adrenal source of androgen excess is suspected [10].

Karyotype analysis (47,XXY) is appropriate in younger men with primary hypogonadism, small firm testes, and tall stature, as Klinefelter syndrome affects roughly 1 in 660 males and often goes undiagnosed until fertility evaluation [22].

The goal of repeat testing on TRT is straightforward: confirm that trough testosterone sits between 400 and 700 ng/dL (mid-normal range), hematocrit stays below 54%, and PSA does not rise by more than 1.4 ng/mL per year [5].